Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

810

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

July 31, 2006

Conditions
Diabetes, Type 2
Interventions
DRUG

Atorvastatin and Omega-3 fatty acids

Trial Locations (59)

KA12 OAY

Pfizer Investigational Site, Irvine

BL4 9AH

Pfizer Investigational Site, Farnworth

CF14 9BB

Pfizer Investigational Site, Thornhill

PL23 1DT

Pfizer Investigational Site, Fowey

PL15 9HH

Pfizer Investigational Site, Launceston

TR18 4JH

Pfizer Investigational Site, Penzance

TR19 7HX

Pfizer Investigational Site, Penzance

PL12 6DL

Pfizer Investigational Site, Saltash

PL26 7RL

Pfizer Investigational Site, St Austell

DL16 6QA

Pfizer Investigational Site, Darlington

DL5 5NH

Pfizer Investigational Site, Newton Aycliffe

RH10 1LL

Pfizer Investigational Site, Three Bridges

PL5 3JB

Pfizer Investigational Site, Plymouth

PL6 7TH

Pfizer Investigational Site, Plymouth

TN39 4SP

Pfizer Investigational Site, Bexhill-on-Sea

TN40 2SD

Pfizer Investigational Site, Bexhill-on-Sea

BA2 4JT

Pfizer Investigational Site, Bath

S18 1RU

Pfizer Investigational Site, Dronfield, Sheffield

CR7 7JN

Pfizer Investigational Site, Surrey

CO9 1EX

Pfizer Investigational Site, Halstead

GL10 2NG

Pfizer Investigational Site, Stonehouse

SO31 7DQ

Pfizer Investigational Site, Southampton

TN11 9HL

Pfizer Investigational Site, Hildenborough

FY5 3LF

Pfizer Investigational Site, Thorneton-Clevely

SW12 8EU

Pfizer Investigational Site, Balham

SW6 2HQ

Pfizer Investigational Site, Fulham

SW17 9SJ

Pfizer Investigational Site, Tooting

UB4 0SF

Pfizer Investigational Site, Hayes

NN8 4RW

Pfizer Investigational Site, Wellingborough

BT80 8BN

Pfizer Investigational Site, Cookstown

BA11 1EZ

Pfizer Investigational Site, Frome

KT22 9LE

Pfizer Investigational Site, Fetcham

Unknown

Pfizer Investigational Site, Woking

RH10 7DX

Pfizer Investigational Site, Crawley

LS12 1JE

Pfizer Investigational Site, Leeds

BA1 5DQ

Pfizer Investigational Site, Bradford-on-Avon

SN12 6UN

Pfizer Investigational Site, Melksham

SN25 4YZ

Pfizer Investigational Site, Swindon

BA14 7EG

Pfizer Investigational Site, Trowbridge

BA12 9AA

Pfizer Investigational Site, Warminster

S7 2DW

Pfizer Investigational Site, Sheffield

BA2 1NH

Pfizer Investigational Site, Bath

BA2 3HT

Pfizer Investigational Site, Bath

BT4 1NT

Pfizer Investigational Site, Belfast

B37 7TR

Pfizer Investigational Site, Birmingham

HP22 5LB

Pfizer Investigational Site, Bucks

S40 4TF

Pfizer Investigational Site, Chesterfield

SN15 2SB

Pfizer Investigational Site, Chippenham, Wiltshire

TR18 2RE

Pfizer Investigational Site, Cornwall

BT41 3AE

Pfizer Investigational Site, County Antrim, Northern Ireland

DL3 6HZ

Pfizer Investigational Site, Darlington

DD2 5NH

Pfizer Investigational Site, Dundee

DD4 6QY

Pfizer Investigational Site, Dundee

TN40 3RJ

Pfizer Investigational Site, East Sussex

PO32 6RR

Pfizer Investigational Site, Isle of Wight

PO33 2PT

Pfizer Investigational Site, Isle of Wight

N19 5EW

Pfizer Investigational Site, London

SW19 6DA

Pfizer Investigational Site, London

BA13 3JD

Pfizer Investigational Site, Westbury

All Listed Sponsors
collaborator

Churchill Hospital

OTHER

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00141232 - Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter